San Diego-based aTyr Pharma, which is developing biopharmaceuticals focused on inflammation, autoimmune, hematopoietic and metabolic disorders, disclosed Tuesday that it has raised $12M in an additional funding round. The firm said the funding came from existing investors, which include Alta Partners, Cardinal Partners, Polaris Ventures and Paul Schimmel. The funding comes on top of $12M from the same venture backers back in April of 2007. More information »